Mizuho Securities analyst Mara Goldstein initiated coverage with a Hold rating on Adaptimmune Therapeutics ( ADAP – Research Report ) today and set a price target of $3.00 . The company’s shares c
In a report released today, Mara Goldstein from Mizuho Securities initiated coverage with a Buy rating on Autolus Therapeutics (AUTL) and a price target
In a report released today, Mara Goldstein from Mizuho Securities initiated coverage with a Buy rating on Autolus Therapeutics (AUTL
In a report released today, Mara Goldstein from Mizuho Securities initiated coverage with a Buy rating on Iovance Biotherapeutics (IOVA) and a price
In a report released today, Mara Goldstein from Mizuho Securities initiated coverage with a Buy rating on Iovance Biotherapeutics ( IOVA – Research Report ) and a price target of $61.00 . The compan
JonesTrading analyst Soumit Roy reiterated a Buy rating on Mirati Therapeutics (MRTX) today and set a price target of $130.00. The company's shares closed
JonesTrading analyst Soumit Roy reiterated a Buy rating on Mirati Therapeutics ( MRTX – Research Report ) today and set a price target of $130.00 . The company’s shares closed last Monday at $93.7
Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) has been given a consensus rating of “Buy” by the nine brokerages that are currently covering the firm, MarketBeat Ratings reports. Three analysts ha
Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) was the target of a significant growth in short interest during the month of March. As of March 31st, there was short interest totalling 708,600 shares,
In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Surface Oncology (SURF), with a price target of $12.00. The company's
In a report released today, Soumit Roy from JonesTrading reiterated a Buy rating on Surface Oncology ( SURF – Research Report ), with a price target of $12.00 . The company’s shares closed last Th
Adaptimmune Therapeutics (NASDAQ:ADAP) was upgraded by equities researchers at BidaskClub from a “hold” rating to a “buy” rating in a report released on Thursday, BidAskClub reports. Separatel

2 Penny Stocks That Could Make You Rich

02:00pm, Monday, 13'th Apr 2020
Adaptimmune Therapeutics and OrganiGram Holdings are two penny stocks that may be worth the risk.
Raymond James & Associates boosted its stake in Adaptimmune Therapeutics PLC – (NASDAQ:ADAP) by 13.7% in the fourth quarter, according to the company in its most recent 13F filing with the Securitie
JonesTrading analyst Soumit Roy initiated coverage with a Buy rating on Aileron Therapeutics (ALRN) today and set a price target of $5.00. The company's
Click to get the best stock tips daily for free!

Top Fintech Company

StockInvest.us featured in The Global Fintech Index 2020 as the top Fintech company of the country.

Full report by FINDEXABLE